Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Fineline Cube Aug 20, 2026
Company Deals

VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation

Fineline Cube Aug 20, 2026
Company Deals

LEO Pharma to Acquire Global Rights to Dersimelagon From Tanabe – Late‑Stage Oral Therapy for Rare Protoporphyrias Nears FDA Decision

Fineline Cube Aug 20, 2026
Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Policy / Regulatory

China’s CDE Opens Public Comment on “Pioneer Program” for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year

Fineline Cube Aug 20, 2026
Company Drug

Abbisko Wins NMPA IND Clearance for Pan‑KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light

Fineline Cube Aug 20, 2026
Company Drug

Haisco Pharmaceutical Wins NMPA Clinical Approval for Nav1.8 Inhibitor HSK51155 – Pain Drug Licensed to AbbVie in USD 700 Million Deal Advances in China

Fineline Cube Aug 19, 2026
Company Deals

Anhui Anke Biotechnology Receives NMPA Approval for Clinical Trial of HPV-Targeting mRNA Drug AFN0328

Fineline Cube Jul 24, 2024

China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced that it has received...

Company Deals

Novogene and Becton, Dickinson Partner to Advance Single Cell Sequencing Technologies

Fineline Cube Jul 24, 2024

Novogene (SHA: 688315), a genomic services and solutions provider based in Beijing and operating globally,...

Company Deals

Shanghai Desano and Chongqing Kangfude Partner to Establish Peptide Drug Production Base in China

Fineline Cube Jul 24, 2024

Shanghai Desano Biopharmaceutical Co., Ltd, a leading biopharmaceutical company based in China, has entered into...

Company Deals

TowardPi Medical Partners with OCULUS Iberia to Introduce Advanced OCTA Technology to Spain

Fineline Cube Jul 24, 2024

TowardPi (Beijing) Medical Technology Ltd, a Chinese medical technology company specializing in ophthalmic imaging, has...

Company Drug

ViiV Healthcare’s Dovato Shows Non-Inferior Efficacy and Less Weight Gain in Pivotal PASO DOBLE Study

Fineline Cube Jul 24, 2024

ViiV Healthcare, the HIV-focused subsidiary majority-owned by GSK with Pfizer and Shionogi as shareholders, has...

Company

Pfizer Launches SGD 1 Billion API Plant Expansion in Singapore, Creating 250 New Jobs

Fineline Cube Jul 24, 2024

Pfizer Inc., (NYSE: PFE) a leading global pharmaceutical company, has announced the opening of an...

Policy / Regulatory

China’s NHSA Updates DRG/DIP Payment Reform Program with New Exclusion Mechanisms and Timelines

Fineline Cube Jul 23, 2024

The National Healthcare Security Administration (NHSA) in China has issued a notification outlining several updates...

Company Drug

Jiangsu Hansoh’s Loxenatide Matches Dapagliflozin in Diabetes Nephropathy Clinical Trial

Fineline Cube Jul 23, 2024

Jiangsu Hansoh Pharmaceutical Co., Ltd, a leading pharmaceutical company based in China, has published the...

Company Deals

Innovax Biotech and GSK Terminate Collaboration on Next-Generation HPV Vaccine

Fineline Cube Jul 23, 2024

Xiamen Innovax Biotech Co., Ltd., a Chinese biopharmaceutical company, and GlaxoSmithKline (GSK, NYSE: GSK), a...

Company Drug

China’s NMPA Considers Breakthrough Designations for Xiangxue and Innostellar’s Therapies

Fineline Cube Jul 23, 2024

Xiangxue Pharmaceutical Co., Ltd (SHE: 300147) and Innostellar Biotherapeutics Co., Ltd have both been noted...

Company Deals

Aligos Therapeutics and Xiamen Amoytop Biotech Partner to Test Hepatitis B Combination Therapy

Fineline Cube Jul 23, 2024

Aligos Therapeutics Inc. (NASDAQ: ALGS), a San Francisco-based biotechnology company, has announced a clinical trial...

Company Drug

Johnson & Johnson Pursues FDA Approval for Spravato as Monotherapy for Treatment-Resistant Depression

Fineline Cube Jul 23, 2024

Johnson & Johnson (J&J, NYSE: JNJ), a leading global healthcare company, is pursuing expanded approval...

Company Policy / Regulatory

WuXi AppTec Spends Over USD 360,000 on US Lobbying Amid Biosecure Act Deliberations

Fineline Cube Jul 23, 2024

Endpoints News has reported that WuXi AppTec Co., Ltd, (SHA: 603259) a China-based Contract Development...

Company

Sino Biopharm’s Subsidiary invoX Restructures, Focusing on CD137/PD-L1 Molecule FS222

Fineline Cube Jul 23, 2024

UK-based biotechnology company invoX, an international subsidiary established by China-based Sino Biopharmaceutical Group in 2021,...

Company Deals

China’s Triastek and Germany’s BioNTech Join Forces for 3D Printed Oral Therapeutics

Fineline Cube Jul 23, 2024

Triastek Inc., a China-based pharmaceutical company specializing in 3D printing technology, has entered into a...

Company Drug

RemeGen’s Telitacicept Earns Full NMPA Approval for RA Treatment and PMN Clinical Study Green Light

Fineline Cube Jul 23, 2024

RemeGen (HKG: 9995), a biopharmaceutical company based in China, has announced that the National Medical...

Policy / Regulatory

NMPA Suspends Import and Sale of SAMO S.p.A Knee and Hip Prosthesis Systems

Fineline Cube Jul 23, 2024

The National Medical Products Administration (NMPA) has issued a notice to suspend the import, sale,...

Company Deals

Fosun Pharma and Kite Pharma Inject USD 28.5 Million into Joint Venture for CAR-T Therapy Development

Fineline Cube Jul 23, 2024

Shanghai Fosun Pharmaceutical Group Co., Ltd (SHA: 600196; HKG: 2196) and Kite Pharma, a subsidiary...

Company Deals

Shanghai Medicilon and Jiangsu Hengrui Join Forces to Advance Pre-Clinical Drug Evaluation

Fineline Cube Jul 23, 2024

Shanghai Medicilon Biomedical Co., Ltd, a leading biopharmaceutical company based in China, has entered into...

Company Drug

AccurEdit Therapeutics Receives CDE Approval for Gene Editing Drug ART001 Targeting Amyloidosis

Fineline Cube Jul 23, 2024

AccurEdit Therapeutics (Suzhou) Co., Ltd, a leading specialist in gene editing therapies based in China,...

Posts pagination

1 … 370 371 372 … 710

Recent updates

  • Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review
  • China’s CDE Opens Public Comment on “Pioneer Program” for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year
  • CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World’s First CAR‑T for Solid Tumors; Cash Runway Seen Into 2030
  • Abbisko Wins NMPA IND Clearance for Pan‑KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light
  • VectorBuilder and Lir Therapeutics Forge AI Collaboration to Optimize AAV Capsids for Clinical Translation
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Simcere Secures Greater China Rights to Reyoung Bio’s Long‑Acting RSV Antibody RB0026 Under Priority Review

Company Policy / Regulatory

China’s CDE Opens Public Comment on “Pioneer Program” for Cell and Gene Therapy Products, Capping Intake at 15 Drugs Per Year

Company

CARsgen 1H 2026: Satricabtagene Autoleucel Wins NMPA Approval as World’s First CAR‑T for Solid Tumors; Cash Runway Seen Into 2030

Company Drug

Abbisko Wins NMPA IND Clearance for Pan‑KRAS Inhibitor ABSK211 in Advanced Solid Tumors, Following FDA Green Light

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.